Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

Completed · Phase 2

Conditions studied: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma

In brief

This phase II trial studies the side effects of giving bortezomib together with vorinostat and to see how well it works in treating patients with multiple myeloma who have undergone autologous stem cell transplant. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat after an autologous stem cell transplant may stop the growth of any cancer cells that remain after transplant.

Key facts

Study ID: NCT00839956
Run by: Fred Hutchinson Cancer Center
People needed: 31
Starts: 2009-02-01
Expected to finish: 2017-03-31
Last updated by the study team: 2017-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Any autologous patient who underwent high dose melphalan (>= 140 mg/m\^2) therapy or peripheral blood stem cell (PBSC) rescue for any stage of multiple myeloma and did not participate in another clinical transplant trial whose primary endpoint is also evaluating long-term, disease-free survival, or survival
Platelet count (transfusion independent) > 75,000 cells/mm\^3 and absolute granulocyte count > 1500 cells/mm\^3 for 5 calendar days after recovery from high dose therapy
Consenting for study between 30 days to 120 days after transplant
Female patient of childbearing potential has a negative serum pregnancy test beta-hCG within 72 hours prior to receiving the first dose of vorinostat
Female patient is either post-menopausal, free from menses for >= 2 years, surgically sterilized, or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agrees to abstain from heterosexual activity throughout the treatment on study, starting with visit 1 and for 3 months afterward
Male patient agrees to use an adequate method of contraception for the duration of the treatment on study and for 3 months afterward

You may not qualify if…

Eastern Cooperative Oncology Group (ECOG) performance status >= 2
A left ventricular ejection fraction less than 45% pre-transplant
Congestive heart disease with transplant, history of myocardial infarction (MI), history of coronary artery disease, or prolonged corrected QT interval (QTC)
Total bilirubin greater than 2 mg/ml (unless history of Gilbert's disease)
Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) > 2.5 x upper limit of normal (ULN)
Creatinine clearance < 20 ml/minute, calculated by Cockroft-Gault formula or measured urine
Cannot give informed consent
Untreated systemic infection
Poorly-controlled diabetes mellitus (DM)
>= grade 3 peripheral neuropathy
Prior history of human immunodeficiency virus (HIV) positivity with pre-transplant evaluation or known history of hepatitis B or C
Previous history of hypersensitivity to Bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogs
Require therapeutic anticoagulation treatment, especially with coumadin
Potassium (K) and magnesium (Mg) < normal limits
Patient who has had chemotherapy, radiotherapy, or biological therapy, within 30 days (42 days for nitrosoureas or mitomycin C) prior to initial dosing with study drug(s) or who has not recovered from adverse events due to agents administered more than 30 days earlier; patients who have received localized consolidation radiation to bone only less than 30 days prior to study entry are allowed
Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drugs
Patient had prior treatment with an histone deacetylase inhibitor (HDAC) inhibitor (e.g., romidespin [depsipeptide], NSC-630176, MS 275, LAQ-824, belinostat [PXD-101], LBH589, MGCD0103, CRA024781, etc.)
Patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study
Patients who have received such compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout period
History of central nervous system (CNS) disease
Symptomatic ascites or pleural effusions
Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse
Patient is pregnant or breast-feeding, or expecting to conceive or father children within the projected duration of the study
Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; non-melanoma skin cancer; adequately treated localized prostate carcinoma with prostate-specific antigen (PSA) < 1.0; or who has undergone potentially curative therapy with no evidence of disease for five years, and/or who is deemed at low risk for recurrence by his/her treating physician

Where it is running

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.